Polar Capital Funds PLC - Biotechnology Fund I Inc GBP


New for 2018. Backs biotech companies of all sizes

Polar Capital Biotechnology, a £200 million fund, is a newcomer for 2018, having replaced the £500 million Axa Framlington Biotech fund. It has failed to beat its benchmark over three and five years, while Polar Capital Biotechnology has done so handsomely.It aims to preserve capital and achieve long-term capital growth by investing in companies across the biotechnology ecosystem. Lead fund manager David Pinniger has run the fund since its launch in 2013. He is supported by a team of five further healthcare sector specialists who have more than 100 years of industry experience between them.The team believe that a concentrated and actively managed portfolio is the best way for investors to exploit the investment opportunities found in the biotech sector. They use fundamental analysis to select a portfolio of typically 40 to 60 stocks (48 at the end of 2017). Their strategy is to use an unconstrained approach to portfolio construction and stock selection, in particular to invest beyond the mainstream larger biotechnology companies that dominate the Nasdaq Biotechnology index.At the end of 2017, the fund had 45 per cent in large companies, 28 per cent in small companies and 24 per cent in medium-sized companies. The managers are able to seek investments worldwide, but given the nature of the industry have most of the fund's assets (70 per cent) in the US. They also have exposure across Europe, and to China and Australia.The fund levies a 10 per cent performance fee, but we deem this to be acceptable for a specialist fund investing in this area.

Narrative and ratings content all as of 01 January 2018.

See all Money Observer rated funds
Polar Capital Funds PLC - Biotechnology Fund I Inc GBP
Polar Capital LLP
Open Ended Investment Company
1.23 %
Risk Rating
3 Year Sharpe
3 Year Alpha
0 %
NASDAQ Biotechnology TR USD
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation.
Holding %
Alexion Pharmaceuticals Inc 7.81 %
Regeneron Pharmaceuticals Inc 6.08 %
Incyte Corp 5.68 %
Gilead Sciences Inc 5.23 %
BeiGene Ltd ADR 5.10 %
argenx SE 5.05 %
Celgene Corp 4.13 %
Biogen Inc 3.99 %
Evotec AG 3.90 %
Vertex Pharmaceuticals Inc 3.76 %
Region %
United States 73.40 %
Eurozone 17.90 %
Sector %
Healthcare 100.00 %
Polar Capital LLP
SW1E 5JD, London, United Kingdom
Legal Structure
Open Ended Investment Company


David Pinniger
Joined 10/31/2013

David joined Polar Capital in August 2013 as a Fund Manager within the healthcare team. He has over 14 years’ investment experience in the healthcare sector. Prior to joining Polar Capital, for five years David was Portfolio Manager of the International Biotechnology Trust at SV Life Sciences

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.